Health-related quality of life or quantity of life: A difficult trade-off in primary brain tumors?

Seminars in Oncology

Volumn 41, Issue 4, 2014, Pages 541-552

  Dirven, Linda ^a   Reijneveld, Jaap C ^a,b   Taphoorn, Martin J B ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; DEXAMETHASONE; ENZASTAURIN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; COGNITIVE DEFECT; DISABILITY; ELDERLY CARE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QLQ-BN20 QUESTIONNAIRE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QLQ-C30 QUESTIONNAIRE; EXPERIMENTAL THERAPY; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL QUESTIONNAIRE; GLIOBLASTOMA; GOLD STANDARD; HUMAN; KARNOFSKY PERFORMANCE STATUS; MD ANDERSON SYMPTOM INVENTORY; NEUROLOGIC DISEASE; NEUROSURGERY; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSYCHOLOGICAL WELL BEING; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RATING SCALE; SCORING SYSTEM; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; SURVIVAL RATE; SYSTEMIC THERAPY; TUMOR GROWTH; TUMOR RECURRENCE; BRAIN NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; HEALTH STATUS; LONGEVITY; MORTALITY; PSYCHOLOGY;

BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HEALTH STATUS; HUMANS; LONGEVITY; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84906773010     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.06.002     Document Type: Article

References (80)

1. D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-Xuan, and J.Y. Delattre Primary brain tumours in adults Lancet 379 2012 1984 1996
2. A. Behin, K. Hoang-Xuan, A.F. Carpentier, and J.Y. Delattre Primary brain tumours in adults Lancet 361 2003 323 331
3. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, and M.J. Taphoorn et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
4. J.D. Olson, E. Riedel, and L.M. DeAngelis Long-term outcome of low-grade oligodendroglioma and mixed glioma Neurology 54 2000 1442 1448
5. F. Pignatti, M. van den Bent, D. Curran, C. Debruyne, R. Sylvester, and P. Therasse et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma J Clin Oncol 20 2002 2076 2084
6. C. Hartmann, B. Hentschel, M. Tatagiba, J. Schramm, O. Schnell, and C. Seidel et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17 2011 4588 4599
7. N.K. Aaronson, M.J. Taphoorn, J.J. Heimans, T.J. Postma, C.M. Gundy, and G.N. Beute et al. Compromised health-related quality of life in patients with low-grade glioma J Clin Oncol 29 2011 4430 4435
8. M.J. Taphoorn, R. Stupp, C. Coens, D. Osoba, R. Kortmann, and M.J. van den Bent et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial Lancet Oncol 6 2005 937 944
9. M.J. Taphoorn, M.J. van den Bent, M.E. Mauer, C. Coens, J.Y. Delattre, and A.A. Brandes et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial J Clin Oncol 25 2007 5723 5730
10. N.K. Aaronson Quality of life: what is it? How should it be measured? Oncology 2 1988 69 76
11. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009 December. www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. [Accessed 29 October. 2013].
12. J.M. Giesinger, M. Golser, A. Erharter, G. Kemmler, G. Schauer-Maurer, and G. Stockhammer et al. Do neurooncological patients and their significant others agree on quality of life ratings? Health Qual Life Outcomes 7 2009 87
13. D.J. Milne, L.L. Mulder, H.C. Beelen, P. Schofield, G.I. Kempen, and S. Aranda Patients" self-report and family caregivers" perception of quality of life in patients with advanced cancer: how do they compare? Eur J Cancer Care (Engl) 15 2006 125 132
14. K.C. Sneeuw, N.K. Aaronson, M.A. Sprangers, S.B. Detmar, L.D. Wever, and J.H. Schornagel Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients J Clin Epidemiol 51 1998 617 631
15. S. McPhail, E. Beller, and T. Haines Two perspectives of proxy reporting of health-related quality of life using the Euroqol-5D, an investigation of agreement Med Care 46 2008 1140 1148
16. K.C. Sneeuw, N.K. Aaronson, D. Osoba, M.J. Muller, M.A. Hsu, and W.K. Yung et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer Med Care 35 1997 490 506
17. N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, and N.J. Duez et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
18. D. Osoba, N.K. Aaronson, M. Muller, K. Sneeuw, M.A. Hsu, and W.K. Yung et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires Qual Life Res 5 1996 139 150
19. P.M. Fayers, N.K. Aaronson, K. Bjordal, M. Groenvold, D. Curran, and A. Bottomley The EORTC QLQ-C30 Scoring Manual 3rd ed. 2001 European Organization for Research and Treatment of Cancer Brussels
20. D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144
21. D.F. Cella, D.S. Tulsky, G. Gray, B. Sarafian, E. Linn, and A. Bonomi et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
22. M.A. Weitzner, C.A. Meyers, C.K. Gelke, K.S. Byrne, D.F. Cella, and V.A. Levin The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors Cancer 75 1995 1151 1161
23. K.J. Yost, and D.T. Eton Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience Eval Health Prof 28 2005 172 191
24. C.S. Cleeland, T.R. Mendoza, X.S. Wang, C. Chou, M.T. Harle, and M. Morrissey et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory Cancer 89 2000 1634 1646
25. T.S. Armstrong, T. Mendoza, I. Gning, C. Coco, M.Z. Cohen, and L. Eriksen et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) J Neurooncol 80 2006 27 35
26. J.A. Sloan, and A. Dueck Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials J Biopharm Stat 14 2004 73 96
27. I. Bosma, J.C. Reijneveld, L. Douw, M.J. Vos, T.J. Postma, and N.K. Aaronson et al. Health-related quality of life of long-term high-grade glioma survivors Neuro Oncol 11 2009 51 58
28. C. Yavas, F. Zorlu, G. Ozyigit, M. Gurkaynak, G. Yavas, and D. Yuce et al. Health-related quality of life in high-grade glioma patients: a prospective single-center study Support Care Cancer 20 2012 2315 2325
29. J. Salo, A. Niemelä, M. Joukamaa, and J. Koivukangas Effect of brain tumour laterality on patients' perceived quality of life J Neurol Neurosurg Psychiatry 72 2002 373 377
30. M. Klein, N.H. Engelberts, H.M. van der Ploeg, D.G. Kasteleijn-Nolst Trenité, N.K. Aaronson, and M.J. Taphoorn et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life Ann Neurol 54 2003 514 520
31. N. Sanai, M.Y. Polley, M.W. McDermott, A.T. Parsa, and M.S. Berger An extent of resection threshold for newly diagnosed glioblastomas J Neurosurg 115 2011 3 8
32. J.S. Smith, E.F. Chang, K.R. Lamborn, S.M. Chang, M.D. Prados, and S. Cha et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas J Clin Oncol 26 2008 1338 1345
33. E.F. Chang, M.B. Potts, G.E. Keles, K.R. Lamborn, S.M. Chang, and N.M. Barbaro et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas J Neurosurg 108 2008 227 235
34. A.S. Jakola, S. Gulati, C. Weber, G. Unsgård, and O. Solheim Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study PLoS One 6 2011 e28592
35. A.S. Jakola, G. Unsgård, and O. Solheim Quality of life in patients with intracranial gliomas: the impact of modern image-guided surgery J Neurosurg 114 2011 1622 1630
36. P.D. Brown, P.A. Decker, T.A. Rummans, M.M. Clark, M.H. Frost, and K.V. Ballman et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life Am J Clin Oncol 31 2008 163 168
37. N. Laperriere, L. Zuraw, and G. Cairncross Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review Radiother Oncol 64 2002 259 273
38. G.M. Kiebert, D. Curran, N.K. Aaronson, M. Bolla, J. Menten, and E.H. Rutten et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group Eur J Cancer 34 1998 1902 1909
39. L. Douw, M. Klein, S.S. Fagel, J. van den Heuvel, M.J. Taphoorn, and N.K. Aaronson et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up Lancet Neurol 8 2009 810 818
40. T.J. Postma, M. Klein, C.C. Verstappen, J.E. Bromberg, M. Swennen, and J.A. Langendijk et al. Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma Neurology 59 2002 121 123
41. F. Keime-Guibert, O. Chinot, L. Taillandier, S. Cartalat-Carel, M. Frenay, and G. Kantor et al. Radiotherapy for glioblastoma in the elderly N Engl J Med 356 2007 1527 1535
42. A. Ernst-Stecken, O. Ganslandt, U. Lambrecht, R. Sauer, and G. Grabenbauer Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma J Neurooncol 81 2007 287 294
43. E.J. Habets, M.J. Taphoorn, S. Nederend, M. Klein, D. Delgadillo, and K. Hoang-Xuan et al. Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors J Neurooncol 116 2014 161 168
44. D. Osoba, M. Brada, W.K. Yung, and M. Prados Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme J Clin Oncol 18 2000 1481 1491
45. K. Hilverda, I. Bosma, J.J. Heimans, T.J. Postma, W. Peter Vandertop, and B.J. Slotman et al. Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings J Neurooncol 97 2010 89 94
46. M.S. van Breemen, E.B. Wilms, and C.J. Vecht Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management Lancet Neurol 6 2007 421 430
47. M. de Groot, L. Douw, E.M. Sizoo, I. Bosma, F.E. Froklage, and J.J. Heimans et al. Levetiracetam improves verbal memory in high-grade glioma patients Neuro Oncol 15 2013 216 223
48. R. Ruda, L. Bello, H. Duffau, and R. Soffietti Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments Neuro Oncol 14 Suppl 4 2012 iv55 iv64
49. M. Weller, R. Stupp, and W. Wick Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol 13 2012 e375 e382
50. M. Maschio, L. Dinapoli, F. Sperati, A. Pace, A. Fabi, and A. Vidiri et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life J Neurooncol 104 2011 205 214
51. M. Maschio, L. Dinapoli, F. Sperati, A. Fabi, A. Pace, and A. Vidiri et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life J Neurooncol 106 2012 651 656
52. E.C. Kaal, and C.J. Vecht The management of brain edema in brain tumors Curr Opin Oncol 16 2004 593 600
53. M.J. van den Bent, D. Afra, O. de Witte, M. Ben Hassel, S. Schraub, and Hoang-Xuan et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial Lancet 366 2005 985 990
54. E. Shaw, R. Arusell, B. Scheithauer, J. O"Fallon, B. O"Neill, and R. Dinapoli et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study J Clin Oncol 20 2002 2267 2276
55. B.G. Baumert, W.P. Mason, G. Ryan, J.E. Bromberg, M.J. van den Bent, and K. Hoang-Xuan et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) [abstract] J Clin Oncol (meeting abstracts) 31 Suppl 2013 (abstract 2007)
56. J.C. Reijneveld, A. Bottomley, M.J. Taphoorn, C. Coens, J.E. Bromberg, and W. Mason Health Related Quality of Life results from temozolomide chemotherapy vs. radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the EORTC/NCIC-CTG/TROG/MRC- CTU (EORTC22033-26033) [abstract] Neurooncology (meeting abstracts) suppl 3 2013 vi101 vi105
57. E.G. Shaw, M. Wang, S.W. Coons, D.G. Brachman, J.C. Buckner, and K.J. Stelzer et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802 J Clin Oncol 30 2012 3065 3070
58. G. Cairncross, M. Wang, E. Shaw, R. Jenkins, D. Brachman, and J. Buckner et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 J Clin Oncol 31 2013 337 343
59. M.J. van den Bent, A.F. Carpentier, and A.A. Brandes et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 2006 2715 2722
60. W. Wick, C. Hartmann, and C. Engel et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 2009 5874 5880
61. M.J. van den Bent, A.A. Brandes, M.J. Taphoorn, J.M. Kros, M.C. Kouwenhoven, and J.Y. Delattre et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 J Clin Oncol 31 2013 344 350
62. M.R. Gilbert, M. Wang, K.D. Aldape, R. Stupp, M.E. Hegi, and K.A. Jaeckle et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial J Clin Oncol 31 2013 4085 4091
63. T.S. Armstrong, J.S. Wefel, M. Wang, M.R. Gilbert, M. Won, A. Bottomley Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma J Clin Oncol 31 2013 4076 4084
64. O. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran, and R. Nishikawa et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly diagnosed glioblastoma: mature progression-free survival and preliminary overall survival results in AVAglio [abstract]. Neurooncology (meeting abstracts) 14 suppl 6 2012 vi101 vi105
65. M.R. Gilbert, J. Dignam, M. Won, D.T. Blumenthal, M.A. Vogelbaum, and K.D. Aldape et al. Phase III double-blind placebo-controlled evaluating Bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM) [abstract] J Clin Oncol 31 Suppl 2013 (abstract 1)
66. M.J. Taphoorn, R. Henriksson, A. Bottomley, T. Cloughesy, W. Wick, and W. Mason et al. Health related quality of life (HRQoL) analyses in the AVAGLIO study, a randomized, placebo-controlled phase III trial of bevacizumab, temozolomide and radiotherapy in newly diagnosed glioblastoma [abstract] Neurooncology (meeting abstracts) 15 Suppl 3 2013 iii232
67. T.S. Armstrong, M. Won, J.S. Wefel, M.R. Gilbert, S. Pugh, and M.M. Wendland et al. Comparative impact of tumor and treatment on patient reported outcomes (PROs) in patients with glioblastom (GBM) enrolled in RTOG 0825 [abstract] Neurooncology (meeting abstracts) 15 Suppl 3 2013 iii226
68. J.S. Wefel, S. Pugh, T.S. Armstrong, M.R. Gilbert, M. Won, and M.M. Wendland et al. Longitudinal analysis of neurocognitive outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825 [abstract] Neurooncology (meeting abstracts) 15 Suppl 3 2013 iii97
69. A.A. Yin, L.H. Zhang, J.X. Cheng, Y. Dong, B.l. Liu, and N. Han et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis PLoS One 8 2013 e74242
70. W. Roa, P.M. Brasher, G. Bauman, M. Anthes, E. Bruera, and A. Chan et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial J Clin Oncol 22 2004 1583 1588
71. A. Malmström, B.H. Grønberg, C. Marosi, R. Stupp, D. Frappaz, and H. Schultz et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol 13 2012 916 926
72. W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabataba, and M. Simon et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol 13 2012 707 715
73. G. Minniti, G. Lanzetta, C. Scaringi, P. Caporello, M. Salvati, and A. Arcella et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma Int J Radiat Oncol Biol Phys 83 2012 93 99
74. G. Minniti, C. Scaringi, A. Baldoni, G. Lanzetta, V. De Sanctis, and V. Esposito et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide Int J Radiat Oncol Biol Phys 86 2013 285 291
75. M. Brada, S. Stenning, R. Gabe, L.C. Thompson, D. Levy, and R. Rampling et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma J Clin Oncol 28 2010 4601 4608
76. T.T. Batchelor, P. Mulholland, B. Neyns, L.B. Nabors, M. Campone, and A. Wick et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma J Clin Oncol 31 2013 3212 3218
77. W. Wick, V.K. Puduvalli, M.C. Chamberlain, M.J. van den Bent, A.F. Carpentier, and L.M. Cher et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma J Clin Oncol 28 2010 1168 1174
78. C. Phillips, and G. Thompson What is a QALY? 2nd ed. 2009 Hayward Medical Communications London
79. K. Tolley What are health utilities? 2nd ed. 2009 Hayward Medical Communications London
80. N. Thon, S. Kreth, and F.W. Kreth Personalized treatment strategies in glioblastoma: promoter methylation status Onco Targets Ther 6 2013 1363 1372